The legacy of general health and science information has long emphasized the importance of understanding how environmental and pharmaceutical factors influence population well-being. In this tradition, public health communication has focused on broad preventive measures, such as vaccination and lifestyle modifications, to reduce disease burden. This foundational knowledge provides a framework for evaluating emerging risks associated with novel therapeutic agents. As medical science advances, the same rigorous scrutiny applied to general health contexts must now be directed toward specific occupational exposures. In mass production settings, workers may encounter pharmaceutical compounds, including monoclonal antibodies like avelumab, during manufacturing, handling, or administration. The transition from general health education to occupational exposure concern requires careful consideration of how such agents might interact with biological systems. While the general public benefits from information about medication safety and efficacy, those in production environments face unique, repeated contact with these substances. This shift in focus necessitates an examination of potential risks that extend beyond the patient population to include workers who handle these drugs. The biological plausibility of any association between avelumab exposure and subsequent health outcomes, such as Merkel cell carcinoma risk, must be evaluated within this occupational context, drawing on established principles of toxicology and exposure science without invoking specific mechanistic claims.
Building on the general framework of occupational exposure assessment, we now turn to the specific evidence regarding avelumab. Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294; https://pubmed.ncbi.nlm.nih.gov/29799096). The approval was based on the JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096). However, the biological plausibility of avelumab causing or contributing to Merkel cell carcinoma requires careful examination of mechanistic pathways, clinical presentation, and risk considerations.
Merkel cell carcinoma has two primary etiologies: approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385). The standard treatment for metastatic MCC includes anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab, which show better overall response rates and longer duration of responses compared to conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385). Nevertheless, about 50% of patients do not respond or develop immune-related adverse events (irAEs) due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385). Avelumab, as an immune checkpoint inhibitor, is known to cause overactivation of the immune system, leading to irAEs (https://pubmed.ncbi.nlm.nih.gov/31543781). Reported irAEs include hypercalcaemia secondary to reactivation of sarcoidosis, which was managed with corticosteroids while avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781). The mechanistic pathways linking avelumab to Merkel cell carcinoma are not straightforward. Avelumab is used to treat MCC, not to cause it. However, the question of causation may arise in the context of avelumab-refractory disease or paradoxical effects.
For avelumab-refractory patients, efficient and safe treatment options are lacking, and combined ipilimumab plus nivolumab has been used in such cases, with three out of five patients responding according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294). A multicenter study of the prospective skin cancer registry ADOREG reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381). These data indicate that avelumab is generally effective, but a subset of patients may experience progression or lack of response, which could be misinterpreted as avelumab-related causation. From a risk perspective, the adequacy of warnings regarding avelumab and Merkel cell carcinoma is addressed in the prescribing information and clinical literature. Avelumab is indicated for the treatment of metastatic MCC, and its adverse effects are well-documented, including irAEs. However, there is no evidence in the provided snippets that avelumab directly causes MCC. Instead, the evidence supports that avelumab is a therapeutic agent for MCC, and any new or worsening MCC during treatment would likely be attributed to disease progression rather than drug causation. Causation-related considerations for affected patients should focus on the natural history of MCC, which is aggressive and has a high mortality rate (https://pubmed.ncbi.nlm.nih.gov/33439294; https://pubmed.ncbi.nlm.nih.gov/34445385). The timeline between exposure and documented harm is relevant: avelumab is administered to patients with existing MCC, so any harm, such as lack of response or irAEs, occurs during treatment. For example, hypercalcaemia due to sarcoidosis reactivation was reported during avelumab therapy, with resolution after corticosteroid treatment (https://pubmed.ncbi.nlm.nih.gov/31543781). This demonstrates that irAEs can occur on a timeline consistent with immune checkpoint inhibition, but they are not indicative of avelumab causing MCC.
In summary, the biological plausibility of avelumab causing Merkel cell carcinoma is not supported by the available evidence. Avelumab is an established treatment for MCC, and its use is associated with immune-related adverse events, but not with the induction of MCC. The risk narrative should emphasize that avelumab is a therapeutic agent for MCC, and any adverse outcomes are more likely related to disease progression or irAEs rather than drug causation. Adequate warnings exist in the prescribing information, and patients should be monitored for irAEs and disease progression during treatment.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
No, avelumab is used to treat Merkel cell carcinoma, not cause it. The biological plausibility of avelumab causing MCC is not supported by evidence. Avelumab is an immune checkpoint inhibitor that targets PD-L1 and is approved for metastatic MCC. Any new or worsening MCC during treatment is likely due to disease progression, not drug causation.
Approximately 80% of Merkel cell carcinoma cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385).
Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system. Reported irAEs include hypercalcaemia secondary to reactivation of sarcoidosis, which can be managed with corticosteroids while continuing avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Free and confidential. No obligation — an initial records screening only.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.